Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 6 (June)

1. Looks can be deceiving.
   Obstet Gynecol, 109(6): 1449, 1462-3. [Abstract] [Full-text]
2. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
   Obstet Gynecol, 109(6): 1342-50. [Abstract] [Full-text]
3. Comparing SILAC and two-dimensional gel electrophoresis image analysis for profiling urokinase plasminogen activator signaling in ovarian cancer cells.
   J Proteome Res, 6(6): 2105-12. [Abstract] [Full-text]
4. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids.
   Int J Radiat Oncol Biol Phys, 68(3): 830-8. [Abstract] [Full-text]
5. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
   Cell Signal, 19(7): 1542-53. [Abstract] [Full-text]
6. Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
   J Med Genet, 44(6): 408-11. [Abstract] [Full-text]
7. Tumor promoting properties of the ETS protein MEF in ovarian cancer.
   Oncogene, 26(27): 4032-7. [Abstract] [Full-text]
8. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
   Oncogene, 26(27): 3952-62. [Abstract] [Full-text]
9. Gonadotropins and ovarian cancer.
   Endocr Rev, 28(4): 440-61. [Abstract] [Full-text]
10. Surgical management of women with ovarian cancer.
    Semin Oncol, 34(3): 226-33. [Abstract] [Full-text]
11. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery.
    Health Qual Life Outcomes, 5: 25. [Abstract] [Full-text]
12. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta.
    Cancer Lett, 253(1): 144-53. [Abstract] [Full-text]
13. A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
    Cancer Chemother Pharmacol, 60(3): 459-61. [Abstract] [Full-text]
14. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
    Biochem Pharmacol, 74(2): 191-201. [Abstract] [Full-text]
15. Implementation of intraperitoneal chemotherapy for the treatment of ovarian cancer.
    Clin J Oncol Nurs, 11(2): 221-5. [Abstract] [Full-text]
16. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
    Clin J Oncol Nurs, 11(2): 211-6. [Abstract] [Full-text]
17. Ovarian cancer: an overview of treatment options.
    Clin J Oncol Nurs, 11(2): 201-7. [Abstract] [Full-text]
18. Primary ovarian leiomyosarcoma: a review of the clinical and immunohistochemical features of the rare tumor.
    Obstet Gynecol Surv, 62(7): 480-6. [Abstract] [Full-text]
19. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
    Gynecol Oncol, 106(1): 119-27. [Abstract] [Full-text]
20. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
    Gynecol Oncol, 106(1): 207-10. [Abstract] [Full-text]
21. Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline.
    Gynecol Oncol, 106(1): 181-92. [Abstract] [Full-text]
22. Associations between physical activity and quality of life in ovarian cancer survivors.
    Gynecol Oncol, 106(1): 244-50. [Abstract] [Full-text]
23. Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses?
    Gynecol Oncol, 106(1): 153-9. [Abstract] [Full-text]
24. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Gynecol Oncol, 106(1): 160-3. [Abstract] [Full-text]
25. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
    Gynecol Oncol, 106(1): 112-8. [Abstract] [Full-text]
26. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
    Gynecol Oncol, 106(1): 215-20. [Abstract] [Full-text]
27. The risk of malignancy in post-menopausal women presenting with adnexal torsion.
    Gynecol Oncol, 106(1): 211-4. [Abstract] [Full-text]
28. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 106(1): 221-32. [Abstract] [Full-text]
29. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
    Gynecol Oncol, 106(1): 164-9. [Abstract] [Full-text]
30. Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma.
    Gynecol Oncol, 106(1): 201-6. [Abstract] [Full-text]
31. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases.
    Gynecol Oncol, 106(1): 65-8. [Abstract] [Full-text]
32. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Gynecol Oncol, 106(1): 44-51. [Abstract] [Full-text]
33. Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer.
    Gynecol Oncol, 106(1): 128-31. [Abstract] [Full-text]
34. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Gynecol Oncol, 106(1): 193-200. [Abstract] [Full-text]
35. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.
    Hum Pathol, 38(7): 1074-80. [Abstract] [Full-text]
36. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Gynecol Oncol, 106(1): 75-81. [Abstract] [Full-text]
37. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Gynecol Oncol, 106(1): 69-74. [Abstract] [Full-text]
38. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
    Hum Pathol, 38(7): 1030-6. [Abstract] [Full-text]
39. A patient with 43 synchronous early gastric carcinomas with a Krukenberg tumor and pericardial metastasis.
    Gastric Cancer, 10(2): 135-9. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.